

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Cayston	Page: 1 of 2
Effective Date: 6/9/2025	Last Review Date: 5/27/2025
Applies to: <div style="display: flex; justify-content: space-between; padding: 0 10px;"> <div> <input checked="" type="checkbox"/> Florida Kids <input checked="" type="checkbox"/> Pennsylvania Kids </div> <div> <input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Virginia </div> <div> <input checked="" type="checkbox"/> Maryland </div> </div>	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Cayston under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Cayston is indicated to improve respiratory symptoms in cystic fibrosis patients with *Pseudomonas aeruginosa*.

All other indications are considered experimental/investigational and are not medically necessary.

Applicable Drug List:

Cayston

Policy/Guideline:

Criteria for Initial Approval:

Cystic Fibrosis

Authorization of 12 months may be granted for members 2 years of age and older with cystic fibrosis when *Pseudomonas aeruginosa* is present in airway cultures OR the member has a history of *Pseudomonas aeruginosa* infection or colonization in the airways. Patient must also be unable to take tobramycin 300 mg/5 mL nebulizer solution (generic) for the given diagnosis, due to a trial and inadequate treatment response, or intolerance, or a contraindication.

Criteria for Continuation of Therapy:

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in criteria for initial approval who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: 84 vials per 28 days



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Cayston

Page: 2 of 2

Effective Date: 6/9/2025

Last Review Date: 5/27/2025

Applies to: ☒ Florida Kids ☒ New Jersey ☒ Maryland
☒ Pennsylvania Kids ☐ Virginia

References:

1. Cayston [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019.
2. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689. doi:10.1164/rccm.201207-1160oe
3. Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics. 2016;137(4):e20151784. doi:10.1542/peds.2015-1784